Medpace (NASDAQ:MEDP) Posts Q4 Sales In Line With Estimates But Stock Drops
  • February 10, 2025

Medpace (NASDAQ:MEDP) Posts Q4 Sales In Line With Estimates But Stock Drops

Clinical research company Medpace Holdings (NASDAQ:MEDP) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.7% year on year to $536.6 million. On the other hand, the company’s full-year revenue guidance of $2.16 billion at the midpoint came in 3.5% below analysts’ estimates. Its GAAP profit of $3.67 per share was 24.1% above analysts’ consensus estimates.

Amkor (NASDAQ:AMKR) Misses Q4 Analysts’ Revenue Estimates, Stock Drops
  • February 10, 2025

Amkor (NASDAQ:AMKR) Misses Q4 Analysts’ Revenue Estimates, Stock Drops

Semiconductor packaging and testing company Amkor Technology (NASDAQ:AMKR) fell short of the market’s revenue expectations in Q4 CY2024, with sales falling 7% year on year to $1.63 billion. Next quarter’s revenue guidance of $1.28 billion underwhelmed, coming in 14.1% below analysts’ estimates. Its GAAP profit of $0.43 per share was 16.2% above analysts’ consensus estimates.